Cellular and T cell engager Immunotherapy
Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
Shebli Atrash, MD
hematology & oncology
Levine Cancer Institute
Charlotte, North Carolina, United States